1st Collaborative Assessment – Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk
Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation therapy, a wearable cardioverter defibrillator (WCD). The assessment aimed to provide valid data on clinical […]
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) […]
PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.
The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access the final project plan at the following link: PTJA06 Final Project Plan
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to or were intolerant to […]
OTJA10 – Final Assessment report and related documents are now available
EUnetHTA started an “Error reporting and correction” procedure on 04/05/2020. The reported error was not classified as an error by EUnetHTA and the Assessment Team, therefore no changes to the assessment report were needed. The comments received including the answers from the authoring team are published for transparency reasons. See here. We are pleased to […]
The EUnetHTA Prioritisation List (EPL) 2.0 is now published and available for access
EUnetHTA is pleased to announce the publication of the second iteration of the EPL. As part of the overarching Topic Identitication, Selection and Prioritisation (TISP) task group, the EPL is a valuable strategic tool for companies to identify the significant interest of national HTA bodies in relation to specific listed compounds. EUnetHTA seeks to increase […]
Reminder: Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).
This is a friendly reminder that EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Please be advised that input submissions will be received through 13:00, July 15th.
PTJA04 – “Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.’ Below is the documentation provided by […]
Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).
EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Input submissions will be received through 13:00, July 15th.
OTCA14 ”Robot-assisted surgery in thoracic and visceral indications”.” Final Assessment Now Available
We are pleased to announce publication of the collaborative assessment OTCA14 “Robot-assisted surgery for thoracic and visceral surgery”. This is the assessment of the relative effectiveness and safety of robot-assisted surgery for 13 different procedures within the thoracic and visceral surgery area. The assessment is based on evidence from RCTs or –in the absence of […]
